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Abstract
Abl kinase inhibitors targeting the ATP binding pocket are currently employed as potent anti-leukemogenic agents but
drug resistance has become a significant clinical limitation. Recently, a compound that binds to the myristate pocket of Abl
(GNF-5) was shown to act cooperatively with nilotinib, an ATP-competitive inhibitor to target the recalcitrant ‘‘T315I’’
gatekeeper mutant of Bcr-Abl. To uncover an explanation for how drug binding at a distance from the kinase active site
could lead to inhibition and how inhibitors could combine their effects, hydrogen exchange mass spectrometry (HX MS)
was employed to monitor conformational effects in the presence of both dasatinib, a clinically approved ATP-site inhibitor,
and GNF-5. While dasatinib binding to wild type Abl clearly influenced Abl conformation, no binding was detected between
dasatinib and T315I. GNF-5, however, elicited the same conformational changes in both wild type and T315I, including
changes to dynamics within the ATP site located approximately 25 A ˚ from the site of GNF-5 interaction. Simultaneous
binding of dasatinib and GNF-5 to T315I caused conformational and/or dynamics changes in Abl such that effects of
dasatinib on T315I were the same as when it bound to wild type Abl. These results provide strong biophysical evidence that
allosteric interactions play a role in Abl kinase downregulation and that targeting sites outside the ATP binding site can
provide an important pharmacological tool to overcome mutations that cause resistance to ATP-competitive inhibitors.
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Introduction
Proteinkinasesarenowavidlypursuedastherapeutictargetsfora
host of human ailments, especially cancers [1–2]. The vast majority
of reported inhibitors target the ATP binding site but because the
ATP binding pocket is highly conserved among the human protein
kinase, there can be cross-reactivity with a number of other kinases.
This cross-reactivity is, in many cases, therapeutically undesirable.
The search for more potent and target-specific ATP site inhibitors
has been met with limited success making alternative kinase
inhibition approaches involving therapeutics that target sites other
than the ATP binding pocket very attractive. As many protein
kinases have multiple regulatory sites that are often kinase specific,
these sites provide the opportunity to develop non-ATP competitive
protein kinase inhibitors with potentially higher selectivity.
Abl kinase is an important inhibitor target due to the role of the
Bcr-Abl fusion protein in the development of Chronic Myleogen-
ous Leukemia (CML). Imatinib (STI-571, Gleevec) [3], nilotinib
(AMN 107) [4] and dasatinib (BMS-354825) [5] are among the
ATP-competitive inhibitors of Bcr-Abl catalytic activity that
have demonstrated remarkable efficacy in chronic-phase CML
(reviewed in [6–9]). For example, imatinib results in a greater than
80% response rate when patients are treated in the chronic phase
of CML. However, approximately 60% of patients in the blast-
crisis phase will develop resistance to imatinib [10–12]. Drug
resistance can occur upon the emergence of cells expressing point
mutations in Bcr-Abl [9]. Of the more than 50 clinically detected
point mutations in Bcr-Abl, the majority occur in the ATP-binding
pocket and appear to result in a steric impediment to drug binding
[11,13–15]. Other mutations remote from the ATP-binding site
are thought to confer resistance by destabilizing the ‘‘DFG-out’’
conformation required for imatinib binding [5] or thorough
other allosteric mechanisms. Later generation inhibitors such as
nilotinib, dasatinib and bosutinib [16] overcome some of the
resistance created by the majority of the mutations. Both dasatinib
and nilotinib exhibit higher binding affinity for the ATP-site and
can overcome all but the T315I gatekeeper mutation [4,17]. In
addition, other new ATP-competitive inhibitors capable of
inhibiting T315I Bcr-Abl have been reported in conjunction with
co-crystal structures: PPY-A [15], SGX393 [18], and PHA-
739358 [14], AP24163 [19], DSA series compounds [20], HG-7-
85-01 [21] and AP24534 [22]; see also [23].
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1We previously reported on the discovery of GNF-2, a small
molecule inhibitor of Bcr-Abl dependent cell proliferation [24].
Based upon mutational analysis, GNF-2 was found to bind not to
the ATP pocket, but instead to the myristate binding pocket
located at the C-terminus of the Abl kinase domain. Studies with
drug resistant mutants showed that GNF-2 maintains potency
against a subset of the clinically relevant imatinib-resistant Bcr-Abl
mutants (e.g., E255V, Y253H), but was surprisingly much weaker
against the T315I gatekeeper mutant [24]. Further evidence
showed that GNF-2 compounds do indeed bind to the myristate
pocket [25] and effectively inhibit kinase activity on their own.
In the current work, we set out to understand mechanistically
how GNF compounds inhibit kinase activity. In addition to
potentially changing the conformation of the aI helix, GNF-2
binding could allosterically influence the catalytic site resulting in
kinase inhibition through an as of yet unknown mechanism. This
hypothesis has validity because there appears to be more to the
effect of the GNF inhibitor than enhancement of SH2 docking to
the kinase domain. GNF-2 and GNF-5 are not potent cellular
inhibitors of the T315I mutant but combinations of nilotinib [25]
or dasatinib (below) with GNF-5 are very effective inhibitors of
T315I both in vitro and in vivo. The ability of the T315I mutation to
activate Abl [26] and the inability of T315I to be potently
inhibited by GNF-2/5 suggests that this mutation may cause a
more widespread conformational rearrangement of the kinase
domain that partially uncouples it from allosteric control by the
myristic acid pocket in the large lobe. In addition, because other
sites of both activating mutations and inhibitor binding can occur
well outside of the Abl active site, there seems to be evidence
supporting the existence of long-range conformational coupling
within the Abl kinase core. Therefore, allosteric inhibitors that
target the Abl kinase core may function by altering the
conformational dynamics of the active site and its ability to bind
to ATP competitive inhibitors.
Hydrogen exchange (HX) mass spectrometry (MS) was used to
study the conformational effects that result from binding of
dasatinib and GNF-5, both individually and in combination, to
wild-type Abl core (a construct containing the NCap, SH3, SH2
and the kinase domain) and a T315I mutant version of Abl core.
All experiments were performed with the Abl core expressed in E.
coli [27]; therefore, this protein was not myristoylated on the N-
terminus and it is in an active conformation, as was shown
previously [27]. While many drug-interaction studies have been
performed with the kinase domain alone, the present results are
some of a few conformational studies that make use of the entire
Abl kinase core.
The results show that dasatinib binding to Abl induced dynamic
changes near the ATP binding site only. There were no significant
changes in hydrogen exchange for Abl T315I in the presence of
dasatinib, illustrating a lack of interaction between dasatinib and
this mutant. As shown previously, GNF-5 binding to the myristic
acid site caused a reduction of hydrogen exchange in both the
myristate and the ATP site [25]. GNF-5 still elicited the same
alterations to hydrogen exchange in T315I as it did in wt Abl.
Finally, in a combination experiment, hydrogen exchange in the
T315I protein in the presence of both dasatinib and GNF-5
demonstrated changes in exchange near the ATP site that were
nearly the same as those seen when dasatinib bound to wild-type
Abl. Taken together, the results provide evidence for allosteric
communication between the two sites and indicate that the factors
leading to dasatinib resistance are somehow overcome by
simultaneous binding of GNF-5 some 25 A ˚ away. Targeting the
Abl myristate binding site can provide an important pharmaco-
logical tool to suppress the rise of drug resistant mutations, and
overcome existent mutations that are resistant to ATP-competitive
inhibitors.
Materials and Methods
Materials
96% formic acid, deuterium oxide (99.9%), sodium chloride
and Tris-hydrochloride were purchased from Sigma-Aldrich (St.
Louis, MO). Acetonitrile and water (W5-4 HPLC grade) were
purchased from Fisher Scientific. Potassium phosphate was
purchased from EMD Biosciences. All chemicals were used
without further purification unless otherwise specified. GNF-5
[25] was synthesized according to published procedures and
dasatinib was purchased from LC Laboratories (Woburn, MA).
Preparation of recombinant proteins
The bacterial expression of human c-Abl kinase (residues 46–
515, Abl 1a numbering [28]) was performed as previously
described [29]. A pET-28a encoded Abl was co-expressed with
YopH phosphatase in Escherichia coli BL21DE3 cells. Cultures
were grown to an OD600 of 1.2 at 37uC, cooled for 1 h with
shaking at 18uC prior to induction for 16 h at 18uC with 100 mM
IPTG. Cells were harvested by 10 min centrifugation at 7000 g at
4uC and resuspended in 50 mM Tris (pH 8.0), 500 mM NaCl,
5% glycerol, 25 mM imidazole (buffer A). Insoluble protein and
cell debris of cell lysate were sedimented by centrifugation at
40,000 g for 40 minutes at 4uC. The supernatant was loaded onto
a Ni affinity column (HisTrap FF, GE Lifescience), equilibrated
with buffer A. The loaded column was washed with five column
volumes of buffer A, and protein was eluted with a linear gradient
of 0–50% of buffer B (Buffer A plus 0.5 M imidazole). The peak
fractions were analyzed by SDS-PAGE. Fractions containing the
kinase were pooled and dialyzed against 20 volumes of buffer QA
(20 mM Tris-pH 8.0, 100 mM NaCl, 5% glycerol, 1 mM DTT)
using a 13-kDa molecular weight cutoff membrane. Tobacco etch
virus protease TEV (expressed in bacteria using a plasmid kindly
provided by M. J. Eck lab at DFCI) was added to the pooled
protein to cleave the His tag (the ratio of TEV to total protein was
1 to 60). Dialysis and protease digestion were carried out overnight
at 4uC. Subsequent anion exchange chromatography (HiTrap Q
FF, GE Lifescience) at room temperature was used to remove
protease and phosphatase contaminants. Proteins were eluted with
a linear gradient of 0–35% buffer QB (buffer QA plus 1 M NaCl),
and peak fractions were analyzed by SDS-PAGE.
Purity and mass of all proteins were verified by electrospray
mass spectrometry (see Supplemental Figure S1). The proteins
were not myristoylated or Ser69 phosphorylated. No inhibitors or
ATP/Mg
2+ were used during purification of Abl proteins or data
acquisition. See Ref. [27] for amino acid sequence information.
Kinetic characterization of Abl inhibition
The ATP/NADH-coupled assay system in a 96-well format was
used to determine the initial velocity of Abl tyrosine kinase
catalyzed peptide phosphorylation. The reaction mixture con-
tained 20 mM Tris-HCl, (pH 8.0), 50 mM NaCl, 10 mM MgCl2,
2 mM PEP [2-(Phosphonooxy)- 2-propenoic acid, Sigma-Aldrich,
cat. P-7002) and 20 mM Abl peptide substrate (EAIYAAP-
FAKKK, New England Biolabs, Cat No. P6051L), fixed or varied
(to determine inhibitor kinetic parameters) concentration of
inhibitor applied, 1/50 of the final reaction mixture volume of
PK/LDH enzyme (pyruvate kinase/lactic dehydrogenase enzymes
from rabbit muscle, Sigma-Aldrich, cat. P-0294), 160 mM NADH,
0.16 mM Abl, and ATP added last to start the reaction.
Absorbance data were collected every 20 s at 340 nm using a
Allostery in Abl Kinase
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reaction was simplified to two one-substrate reactions to determine
ATP kinetic parameters and inhibitor parameters separately.
When determining ATP parameters, the inhibitor concentration
was kept the constant. When determining inhibition parameters,
the ATP concentration was fixed at 20 mM. Steady-state initial
velocity data were drawn from the slopes of the A340 curves and
fit to the Michaelis-Menten equation to determine Vmax and Km
values. Data were fitted globally using GraphPad Prism (Graph-
Pad Software) and Excel XLfit 4.0 to fit velocity equations for
competitive and mixed inhibition. At a concentration of 3 uM,
GNF-5 does not achieve 100% inhibition of Abl. A concentration
range of 0–3 mM was the range where positive additive effects of
GNF-5 and dasatinib were apparent. Full inhibition of WT Abl
could be achieved at concentrations of in excess of 3 uM.
Cell proliferation assay and measurement of resistant
colony formation
4610
3 wildtype or Bcr-Abl transformed Ba/F3 cells per well
were plated in duplicate in 384-well plates, in RPMI 1640 media
supplemented with 10% FBS, (addition of 10 ng/ml of IL-3 for
wide type Ba/F3 cells). Test compounds in DMSO stocks were
serially diluted in DMSO and added using a 384 pin tool. After
48 h of growth, Bright-Glo reagent (Promega, WI) was added to
each well to determine cell viability as a percentage of growth in
the absence of the compound. Luminescence was read as counts/
sec. XL-fit (IDBS) was used for IC50 analysis. For the resistant
colony formation experiment, cultures containing 1610
4 Ba/F3
cells in 96-well plates were incubated with various concentrations
of GNF-5, dasatinib or both. The cells were continuously exposed
to compound in RPMI 1640 with 10% FBS medium and medium
was changed every three days with fresh inhibitor added each
time. The number of resistant colonies was counted at day 12.
Hydrogen exchange experiments
Hydrogen exchange experiments were performed essentially as
described in Iacob et al [27]. Prior to the addition of deuterium,
Abl was allowed to equilibrate with each drug. GNF-5 and
dasatinib were in 100% DMSO at a concentration of 10 mM. 38
pmol of each protein was incubated with 85 mM dasatinib and
GNF-5 for a protein:inhibitor ratio of 1:7. For a Kd of 0.1 mM,
98% of the proteins were bound to the inhibitor. All mixtures were
incubated for 30 min at room temperature before deuterium
labeling. As a control, proteins were incubated in 20 mM Tris,
100 mM NaCl (pH 8.3) buffer and treated exactly as the inhibitor-
bound proteins.
Deuterium exchange was initiated by dilution of the free or
bound protein with 15-fold 20 mM Tris, 100 mM NaCl (pD 8.3),
D2O buffer at room temperature. At each deuterium exchange
time point (from 10 s to 4 hours) an aliquot from the exchange
reaction was removed and labeling was quenched by adjusting the
pH to 2.6 with an equal volume of quench buffer (50 mM
potassium phosphate, pH 2.6, H2O). Quenched samples were
immediately frozen on dry ice and stored at 280uC until analysis.
The same procedure was used for the labeling of all proteins used
in this study.
Each frozen sample was thawed rapidly to 0uC and injected into
a custom Waters nanoACQUITY UPLC system and analyzed as
described previously [30]. The protein sample was digested using a
Poroszyme immobilized pepsin cartridge (Applied Biosystems)
which was accommodated within the UPLC system. The cooling
chamber of the UPLC system, which housed all the chromato-
graphic elements was held at 1uC for the entire time of the
measurements. The injected peptides were trapped and desalted
for 3 min at 100 mL/min and then separated in 6 min by an 8%–
40% acetonitrile:water gradient at 40 mL/min. The separation
column was a 1.06100.0 mm ACQUITY UPLC C18 BEH
(Waters) containing 1.7 mm particles and the back pressure
averaged 8800 psi at 1uC. The average amount of back-exchange
using this experimental setup was 18%–25%, based on analysis of
highly deuterated peptide standards. Deuterium levels were not
corrected for back-exchange and are therefore reported as relative
[31]; however, all comparison experiments were done under
identical experimental conditions thus negating the need for back-
exchange correction [31]. The UPLC step was performed with
protonated solvents, thereby allowing deuterium to be replaced
with hydrogen from side chains and the amino/carboxy terminus
that exchange much faster than amide linkages [32]. All
experiments were performed in triplicate. The error of determin-
ing the deuterium levels was +/20.20 Da in this experimental
setup.
Mass spectra were obtained with a Waters QTOF Premier
equipped with standard ESI source (Waters Corp., Milford, MA,
USA). The instrument configuration was the following: capillary
was 3.5 kV, trap collision energy at 6 V, sampling cone at 37 V,
source temperature of 100uC and desolvation temperature of
250uC. Mass spectra were acquired over an m/z range of 100 to
2000. Mass accuracy was ensured by calibration with 100 fmol/mL
GFP, and was less than 10 ppm throughout all experiments. The
mass spectra were processed with the software HX-Express [33]
by centroiding an isotopic distribution corresponding to the +2,
+3, or +4 charge state of each peptide. In HX-Express, deuteration
levels were calculated by subtracting the centroid of the isotopic
distribution for peptide ions of undeuterated protein from the
centroid of the isotopic distribution for peptide ions from the
deuterium labeled sample. The resulting relative deuterium levels
were plotted versus the exchange-in time. Identification of the
peptic fragments was accomplished through a combination of
exact mass analysis and MS
E [34] using custom Identity Software
from the Waters Corporation. MS
E was performed by a series of
low-high collision energies ramping from 5–25 V, therefore
ensuring proper fragmentation of all the peptic peptides eluting
from the LC system.
Results and Discussion
Resistance to ATP-competitive kinase inhibitors limits the
duration of response that can be achieved with this class of
therapeutics. The most common resistance mechanism involves
the acquisition of mutations in the ATP-binding site that prevent
drug binding or that increase the affinity for ATP. The most
frequent site of mutation occurs to the so-called gatekeeper residue
which is located towards the rear of the ATP-binding cleft. Many
clinically relevant kinases such as Bcr-Abl, c-Kit, EGFR and
PDGFR possess a threonine residue at the gatekeeper position that
is involved in critical interactions with ATP competitive drugs.
Mutation of this residue to a large hydrophobic amino acid such as
isoleucine or methionine disrupts inhibitor binding without
disrupting the kinase activity of the enzyme. The T315I
gatekeeper mutation is resistant to the three Bcr-Abl inhibitors
that are currently approved for the treatment of Chronic
Myelogenous Leukemia: imatinib, nilotinib and dasatinib. There
are two approaches for developing new drugs that can overcome
ATP-site mutations such as the gatekeeper mutation. The first is to
make new ATP-competitive inhibitors that exploit binding modes
that can circumvent the existing mutations. This approach has
been successfully exploited and several ATP-competitive T315I
Bcr-Abl inhibitors are currently in preclinical development [23].
Allostery in Abl Kinase
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particular mutation that will be disruptive to a given inhibitor. The
second approach is to find allosteric inhibitors that are able to
inhibit kinase activity by binding to sites remote from the ATP-site.
Allosteric inhibitors have been discovered for a number of kinases
[2,35–36]. For example, Bcr-Abl can be effectively inhibited by
compounds that bind to the myristate-binding site such as GNF-2
and GNF-5. Allosteric inhibitors have the potential advantage that
they can potentially be used in combination with ATP-competitive
inhibitors to achieve greater inhibition of the target and make it
more difficult to develop a single mutation that reverses drug
efficacy. Indeed, GNF-5 was recently demonstrated to act addi-
tively with nilotinib to suppress the emergence of resistant Bcr-Abl
alleles and to inhibit T315I Bcr-Abl.
Here we sought to determine whether cooperative inhibition of
wild-type and T315I Bcr-abl could be achieved between the
clinically approved inhibitor dasatinib and GNF-5. Dasatinib is an
ATP-competitive inhibitor but it binds to Bcr-Abl in the active
‘type I’ conformation in contrast to nilotinib which binds to the
inactive conformation. We first evaluated the ability of dasatinib
and GNF-5 (or combinations) to inhibit recombinant Abl using a
pyruvate kinase-lactate dehydrogenase detection system, that
couples the production of ADP to oxidation of NADH which
can be monitored spectrophotometrically [37]. Wild-type, T315I,
and E505K Abl kinases were expressed in bacteria. Inhibition of
wild-type Abl was observed for both inhibitors (Fig. 1A) with GNF-
5 exhibiting an IC50=0.22 mM, dasatinib IC50=0.12 mM using
an ATP concentration of 20 mM, which is close to the apparent
Km under our assay conditions. The myristate site mutant E505K
was inhibited by dasatinib with an IC50=0.02 mM, but not by
GNF-5 (IC50 .10 mM). The T315I mutant was partially inhibited
by dasatinib or GNF-5 in this assay. We next examined whether
combinations of GNF-5 and dasatinib resulted in additive inhibi-
tion of wild-type, T315I, or E505K recombinant Abl proteins.
Strong positive cooperativity was observed for combinations of
GNF-5 and dasatinib on T315I Bcr-Abl with a calculated com-
bination index of 0.34. As expected no additivity was observed
with the E505K myristate site mutant.
We next evaluated the ability of the compounds to inhibit the
proliferation of wild-type and T315I transformed Ba/F3 cells
(Fig. 1B). The proliferation assays demonstrated that greater than
50% inhibition of T315I Bcr-Abl dependent cell growth could be
achieved at a range of GNF-5 and dasatinib concentrations. For
example, at a fixed GNF-5 concentration of 10 mM, dasatinib
inhibits T315I Bcr-Abl-dependent proliferation with an IC50=
20 nM (Supplemental Fig. S2A). The calculated combination
index (CI) for GNF-5 and dasatinib in this assay was 0.65,
indicating a synergistic interaction. We also tested the effect of the
drug combinations on Bcr-Abl and STAT5 phosphorylation by
Western blotting. While 10 mM dasatinib was not able to inhibit
Bcr-Abl autophosphorylation and STAT5 phosphorylation in
T315I Bcr-Abl expressing Ba/F3 cells, the combined treatment
with 10 mM dasatinib plus 0.5, 5, or 10 mM GNF-5 significantly
blocked T315I Bcr-Abl signaling (Supplemental Fig. S2B).
Figure 1. Inhibition of Abl proteins with compounds alone or in combination. A. Enzymatic inhibition (in vitro) of recombinant wild-type
and T315I Abl by dasatinib, GNF-5 and combination treatments. Percent inhibition of wt Abl or T315I Abl by dasatinib and GNF-5 or the combination.
The combination curve (red) contains twice the total drug concentration of the single agent curves due to both drugs being present. B. Synergistic
inhibition of Bcr-Abl T315I transformed Ba/F3 cells. Dose and effect curve of GNF-5, dasatinib and the combination of GNF-5 and dasatinib (1:1 ratio)
on Bcr-Abl T315I transformed cells. The combination curve (red) contains twice the total drug concentration of the single agent curves due to both
drugs being present. C. CI values for fractional growth inhibitions of 0.50, 0.75, and 0.90 in Bcr-Abl T315I cells. Antagonism CI .1.00; additivity
CI=1.00; synergy CI ,1.00.
doi:10.1371/journal.pone.0015929.g001
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and dasatinib on the wild-type Abl in vivo, with calculated
combination indices of 0.69 (data not shown). Much stronger
synergism was observed with the T315I form (CI=0.32), Fig. 1C.
As expected no synergy was observed with the E505K myristate site
mutant (Supplemental Figure S2), confirming that GNF-5 binding
to the myristic acid pocket was responsible for the inhibition [25].
HX MS shows changes upon inhibitor binding
Confident that biologically there was strong evidence for
cooperativity between the two binding sites, we utilized hydrogen
exchange mass spectrometry to try to understand how this synergy
worked mechanistically. The conformational dynamics of each
protein were measured in the presence of various drug
combinations. We previously used this methodology to investigate
conformational changes in Abl upon removal of the myristic acid
group and upon mutation in a down-regulated form of Abl [27].
Both wild-type Abl and the T315I mutant were overexpressed
in E. coli and purified to homogeneity. The purity and mass of the
proteins were verified by electrospray mass spectrometry (Supple-
mental Fig. S1). Note that these proteins are prepared from
bacteria and are not myristoylated on the N-terminus, making
them enzymatically active (see also ref. [27]). Prior to analysis of
the HX of each protein in the presence of inhibitors, a control
experiment was performed in which we compared exchange into
wild-type versus the T315I mutant. This was done to provide the
baseline exchange for both forms so there would be a reference for
comparison when each form was bound to the inhibitors. Wild-
type and T315I were independently exposed to deuterium for
various periods of time ranging from 10 seconds to 4 hours. The
exchange was quenched, each deuterated protein was digested into
peptic fragments, and the location and quantity of deuterium was
determined by mass spectrometry [27,31]. Although a large
number of peptic peptides (,50) were followed, only a few
indicated changes in exchange (Supplemental Fig. S3) during the
time frame of the experiment (4 hours). Data is not shown for
regions in which no changes in HX were detected. Interestingly,
we observed few changes in T315I conformational dynamics
relative to the wild-type form. All changes were consistent with the
incorporation of more deuterium in the T315I form compared
with wild-type Abl and were primarily restricted to the small lobe
of the kinase domain (see Fig. S3).
With baseline exchange for both wild type and the T315I
proteins, inhibitor binding was probed by HX MS. Each inhibitor
was first incubated individually with wild-type Abl or T315I and
regions with differences in HX were observed. Again, most
peptides indicated no difference in deuterium uptake (data not
shown), including all regions of both SH3 and SH2. However a
few areas showed differences in deuterium uptake in the presence
of dasatinib or GNF-5. The deuterium incorporation data for
regions where changes were observed are summarized in Figure 2
(representative examples of the raw mass spectra are shown in Fig.
S4). The changes observed upon inhibitor binding cluster into
several distinct areas: residues 280–298, 318–343 and 516–524.
The three dimensional locations of the changes with dasatinib or
GNF-5 and the combination of both are summarized in Fig. 3A
and B and a key locating each peptide is provided in Supplemental
Fig. S5 (see Ref. [27] for amino acid sequence information).
Interpretation of these results is provided in the follow sections.
Dasatinib causes changes in the small lobe but has no
significant effect on T315I
Wild type Abl was incubated with dasatinib in a 1:7 molar ratio
(protein:inhibitor), so that .98% of the Abl molecules were
bound, based on a Kd of 0.1 mM. The control experiment in
which no dasatinib was present was performed at the same time,
under identical conditions so the exchange differences could be
compared without the need for back-exchange correction
(explained in detail in [31]). Changes in deuterium uptake in
wild-type Abl in the presence of dasatinib were observed in several
peptic peptides, mostly near the ATP binding pocket. For
example, the deuterium incorporation graph for the peptide
280–288 indicates that this peptide was less deuterated when
dasatinib was bound implying protection from solvent or increased
hydrogen bonding in this region. Other regions with changes in
the presence of dasatinib included 318–323, 332–336 and 336–
343. The cumulative error of measuring deuterium uptake in these
assays is approximately 60.20 Da. Any differences larger than that
were considered significant for the purposes of comparing the two
datasets. The changes were grouped according to obvious changes
(.1.0 Da separating the deuterium incorporation curves, after two
replicates were averaged) and subtle changes (0.4–1.0 Da
difference).
The location of the changes in wild type Abl when bound to
dasatinib are shown in Fig. 3A, top left. The bulk of the changes
are surrounding the ATP binding pocket, and are consistent with
stabilization of this region upon dasatinib binding. Dasatinib lies in
the ATP site with the aminothiazole group occupying the site
bound by the adenine group of ATP [38–39]. Previous studies
identified three notable hydrogen bonds between dasatinib and
Abl. One with Met337 (Met318) residue, one with Thr334 (T315)
and one with the carbonyl oxygen of Glu335 (Glu316) [38]. Other
contacts are mainly van der Waals interactions between the phenyl
ring of dasatinib and Leu267 (Leu248), Gly340 (Gly321), Met309
(Met290), Val318 (Val299), Ile332 (Ile313) [38]. The HX MS
results are consistent with protection/stabilization of these amino
acids, as all changes we detected were protection from deuteration
in peptic peptides including these amino acids.
It was shown previously that the P-loop is very flexible even
when dasatinib is bound indicating that for the most part the P
loop does not form a critical interaction with dasatinib [38,40].
Based on molecular dynamics studies it has been hypothesized
that dasatinib can bind to both the active DFG- in and inactive
DFG- out conformations of Abl [38,41]. The HX MS data on
the peptide spanning the P-loop (residues 257–274) illustrated
that when dasatinib is bound to Abl, the amount of deuterium
uptake in this peptide is the same as in unbound protein,
indicating that there are no critical interactions between P-loop
and dasatinib (data not shown). This feature may be advanta-
geous because several imatinib resistant Abl mutations appear in
the P-loop.
In contrast to what was observed for dasatinib binding to wild
type Abl, when dasatinib was incubated at the same molar ratio
with the T315I mutant, no major changes in HX were detected.
For example, compared with wild-type Abl, residues 336–343
displayed no changes in deuterium incorporation when dasatinib
was incubated with T315I (Fig. 2). Subtle changes in the
deuterium uptake were detected in residues 287–298 and in two
overlapping peptides spanning the DFG motif (396–403 and 402–
406), but these changes were relatively minor in comparison with
the changes observed in wild-type Abl and dasatinib (see Fig. 3A,
Fig. S5). Previously it was indicated that dasatinib is involved in a
hydrogen bond with the side chain of T315, and the side chain
methyl group of the threonine is involved in van der Waals
contacts with the 2-chloro-6-methyl phenyl ring [38]. Upon
mutation, these contacts are lost and the bulkier isoleucine side
chain increases steric hindrance to dasatinib binding [15]. The
HX MS data nicely show (Fig. 3) that the loss of binding can be
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PLoS ONE | www.plosone.org 5 January  2011 | Volume 6 | Issue 1 | e15929Figure 2. Deuterium incorporation curves for wild-type and T315I Abl in the presence of dasatinib, GNF-5 or both dasatinib and
GNF-5. Both dasatinib and GNF-5 were present at a molar ratio of 1:7, protein:inhibitor. Only data for the peptides that showed changes in
deuterium uptake in the presence of inhibitors are shown; all other regions indicated no changes in hydrogen exchange in the presence of the
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PLoS ONE | www.plosone.org 6 January  2011 | Volume 6 | Issue 1 | e15929clearly observed and is consistent with the known inability of
dasatinib to inhibit the T315I mutant form of Abl.
GNF-5 binding to wild-type or T315I Abl induces a distant
conformational change
We previously showed that GNF-5, a compound representing a
novel class of allosteric Bcr-Abl inhibitors, specifically binds to the
myristic acid binding pocket [25]. Upon binding, hydrogen
exchange is not only reduced in the myristic acid pocket, but
also at a distance in the ATP site. This allosteric effect is specific to
GNF-5 binding. Mutation of a residue (E505K, see Supplemental
Fig. S6) known to be specific and required for GNF-5 interaction,
and the reduction in kinase activity (Fig. S2), abolishes the
reduction of HX in the ATP site. We now show that GNF-5 can
also elicit the same effects in the T315I mutant.
Figure 3. Summary of the hydrogen exchange results for all binding experiments in this study. In each panel, the ribbon diagram of Abl
(PDB 2F4J, [46]) is shown in the left and the space filling model is shown on the right. The differences in deuterium levels are colored on each peptide where
changes were observed, according to the color code shown. The location of each specific peptide is labeled in Supplemental Fig. S5. Obvious changes (colored
hot pink) were defined as a difference between deuterium exchange-in curves of 1.0 Da or more, subtle changes (colored light yellow) were defined as a
differenceof 0.4–1.0Daand no changes weredefinedasdifferencesof 0.0–0.4Da. TheATPbinding siteis shownbyrenderingthedrugVX-6, already present in
the 2F4J crystal structure. A close-up of the myristic acid binding pocket is shown in Supplemental Fig. S6. Abl structure 2F4J was chosen to interpret the
hydrogen exchange data as it has an extended aI helix thought to be present in the active form of Abl. Although the NCap SH3 domain, SH2 domain and the
SH2-kinase linker are present in the constructs studied, no changes in hydrogen were detected in those regions in the presence of these inhibitors.
doi:10.1371/journal.pone.0015929.g003
inhibitors in the time frame the experiment was performed (4 hours). Data for free or bound forms were acquired under identical conditions, in
duplicate. The error of each data point is 60.20 Da. Note that we have used Abl 1b numbering [45] throughout this work; for example, Abl position
T315 is actually T334 in Abl 1b, but we are using the numbering designation of T315I according to the established clinical conventions [10].
doi:10.1371/journal.pone.0015929.g002
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PLoS ONE | www.plosone.org 7 January  2011 | Volume 6 | Issue 1 | e15929Both wild-type Abl and the T315I mutant form were incubated
with GNF-5 and independently exposed to D2O for various
periods of time as described above. Changes in deuterium
incorporation in the presence of GNF-5 were observed in several
peptides (Fig. 2) and the results were highly similar for both wild-
type or T315I. The peptides 516–524 and 525–534 correspond to
the C-terminal aI-helix in the kinase domain. Both were affected
by GNF-5 binding (Figs. 2, 3, S4C) and the changes were the same
for both wild-type and T315I. After 10 seconds in deuterium,
exchange was reduced by approximately 1 deuterium atom,
implying that the effect was a result of steric occlusion rather than
long-term changes in protein stability or dynamics [42–43].
Furthermore, other peptides located in close proximity to the
myristic pocket showed slightly decreased deuterium uptake when
the GNF-5 was present (Fig. 3A). These results strongly support
previous data which indicate that the location of the GNF-5 is
indeed in the myristic pocket [25] and show that GNF-5 binding
occurs regardless of the T315I mutation.
Hydrogen exchange data in the region 325–343 indicate that
GNF-5 binding alters the protein dynamics in this region. The
change can be observed in the raw mass spectra (Fig. S4B), in the
deuterium uptake curves (Fig. 2) and in the summary shown in
Fig. 3. The change is a decrease in deuterium incorporation, seen
clearly for peptide 325–335 in the wild type Abl in the presence of
GNF-5 [25] but also for peptides 332–336 and 336–343 in the
T315I form. Residues 325–335 correspond to the b-strand that
descends down through the center of the b-sheet in the small lobe
and emerges on the SH3-side of the ATP binding pocket. This
stretch of residues includes the T315I mutation (in Abl 1b
numbering, T315I is at position 334, see note above). Many of the
amide hydrogens in this region are hydrogen bonded due to
participation in the b-sheet of the small lobe, reflected in the small
amount of deuterium that is incorporated at early exchange times
for peptides in this area. However, this region is dynamic because
it can incorporate deuterium over time due to ordinary protein
breathing and other motions. The presence of GNF-5 slows these
motions and prohibits the incorporation of deuterium in peptides
325–335, 332–336 and 336–343. Although the exact mechanistic
details of how distant binding is transmitted through the protein
are not revealed by these data, the ability of GNF-5 to inhibit
kinase activity on its own in both wild-type and T315I Abl (Fig. 1)
must be related to these changes in protein dynamics and point to
an allosteric mechanism by which GNF-5 binding is communi-
cated to the ATP site. This does suggest that upon binding of
GNF-5 there might be a structural reorganization, possibly
communicated via a conformational rearrangement of other parts
of Abl, which disrupts the catalytic machinery located in the ATP
site.
Choi Y. et al have recently demonstrated that GNF-2 requires
Abl SH2 and SH3 domain in order to inhibit kinase activity [44].
Perhaps the GNF class of ligands are able to restore autoinhibi-
tion by binding to the myristate pocket and reinducing the kinked
conformation of the a-helix to permit docking of the SH2, SH3
domain modules onto the back of the kinase domain. If this were
to occur, the autoinhibited conformation would be restored
and hydrogen exchange would resemble that of Abl in the
downregulated, N-terminally myristoylated state (as examined
in [27]). The differences between autoinhibited and active Abl
are clear and can be found in the SH2 domain, the linker and
parts of the small lobe of the kinase domain [27]. We see no
evidence in the current HX MS data for restoration of the
autoinhibited form of Abl upon GNF-5 binding, implying that the
SH2 and SH3 domains are still displaced form their regulatory
positions.
Conformational changes were additive when both GNF-5
and dasatinib were present
Based on the biological data showing synergy between GNF-5
and ATP-competitive inhibitors (Fig. 1), we examined the effects of
binding both dasatinib and GNF-5 to T315I Abl. T315I Abl was
incubated with both drugs in a 1:7:7 ratio (protein:dasatinib:GNF-
5) and deuterium exchange measured. Changes in deuterium
uptake were observed in several regions near the ATP binding site
as well as by the myristic acid pocket (Fig. 3B). One of the most
interesting findings was that a number of peptides in T315I Abl
that showed no reduction in deuterium incorporation in the
presence of dasatinib alone (Fig. 3A, bottom left) showed nearly
the same reduction in deuterium incorporation in dasatinib+GNF-
5 (Fig. 3B) as was seen for dasatinib binding to wild-type Abl
(Fig. 3A, top left). Reduced deuterium incorporation in the
presence of dasatinib+GNF-5 was similar in peptides seen to
change in the presence of GNF-5 only (compare dotted curves in
Fig. 2), and the only additional peptides seen to be modified over
GNF-5 binding alone were 280–288 and 287–298 (Fig. 2). Both
280–288 and 287–298 underwent reduced exchange in wild-type
Abl in the presence of dasatinib. Based on these results, we
conclude that the effects of dasatinib on Abl conformation and
dynamics are restored in the T315I form when GNF-5 is present.
For the T315I mutant therefore, as was shown in the biological
data, two drugs are better than one and the effects on the
conformational dynamics are additive.
Conclusions
Abl can become resistant to inhibition as a result of ATP site
mutations. As shown in our biological assays, alternative inhibitors
that target regions of Abl other than the ATP site seem to be
effective strategies for overcoming resistance. Our results verified
that a double therapy consisting of dasatinib and GNF-5 bound to
T315I can synergistically function to inhibit T315I in biochemical
and cellular assays, as was also shown for nilotinib and GNF-5
[25]. The question was how? How does binding in distant regions
influence kinase activity? We answered the question with HX MS
by showing that GNF-5 binding alters the dynamics properties of
the ATP site in both wild type and T315I forms of Abl. GNF-5
restores the conformational changes that are seen when dasatinib
binds to wild-type Abl. Residues located at positions 325–343 in
the ATP site were most influenced by GNF-5 binding and the
T315I mutation did not alter the ability of GNF-5 to elicit such
changes. These biophysical data should contribute to more
rational application of combinations of inhibitors in the challenge
to overcome inhibitor resistance.
Supporting Information
Figure S1 Correct synthesis, purity and post-translational
modifications for each protein were determined with mass
spectrometry. The raw m/z data are shown on the left and the
transformed, mass only spectra shown on the right. The measured
and theoretical molecular weights are indicated. In the trans-
formed mass spectra, P indicates phosphorylation. To obtain these
data, approximately 150 pmols of each protein were injected onto
a POROS 20 R2 protein trap, desalted with 0.05% trifluroacetic
acid (TFA) at 100 mL/min for 2 minutes, and eluted at 50 mL/min
with a 4 minute linear 15%–75% (v/v) acetonitrile gradient
directly into an LCT-Premier mass spectrometer (Waters Corp.,
Milford, MA, USA) equipped with a standard electrospray source.
The instrument was calibrated with 500 fmol/mL myoglobin and
the mass accuracy was less than 10 ppm. Phosphorylation (+80 or
+160 Da) was observed in the intact protein spectra. The location
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PLoS ONE | www.plosone.org 8 January  2011 | Volume 6 | Issue 1 | e15929of each phosphorylation was determined by trypsin digestion
followed by LC-MS/MS (data not shown). Each recombinant
protein (50 pmol each) was incubated with trypsin (1:20,
trypsin:protein) for 16 hours at 37uC. The resulting peptides were
analyzed with a Waters nanoAcquity UPLC system (1.06100.0
mm ACQUITY C18 BEH column) coupled to a Waters QTof
Premier mass spectrometer. Peptide mass spectra were acquired
over an m/z range of 100 to 2000. Mass accuracy was ensured by
lock-mass calibration with 100 fmol/mL Glu-Fibrinogen peptide,
and was less than 10 ppm throughout all experiments. MS
E was
performed on all parent ions, ramping collision energy from 5-
25V. For wild-type Abl, single phosphorylation corresponded to
modification at Tyr412 and double phosphorylation involved
Tyr412 and Tyr89. For Abl T315I, single phosphorylation was on
Tyr89 and only a small quantity of the molecules contained
phosphoryation at both Tyr89 and Tyr412.
(TIF)
Figure S2 GNF-5 binds to the myristic pocket and inhibits
activity in Bcr-Abl T315I. A. Dasatinib antiproliferative EC50 in
the presence of 0.4 to 10 mM GNF-5 on Ba/F3 cells expressing
T315I and E505K Bcr-Abl. B. Inhibition of Bcr-Abl autopho-
sphoryl-ation was determined by Bcr-Abl immunoprecipitation,
followed by a immunoblot for phospho-Tyr (Tyr412) [4],
phospho-STAT 5 (Tyr694) and total Bcr-Abl (antibody K-12)
from cell lystates obtained after treatment of T315I Bcr-Abl
expressing Ba/F3 with 10 mM of dasatinib and increasing
concentrations of GNF-5 (0, 0.5, 5 and 10 mM) for 90 min.
(TIF)
Figure S3 Comparison of deuterium exchange in wild-type Abl
and T315I. The deuterium uptake curves for six representative
peptides are shown in the left [solid lines: wild-type Abl; dotted
lines: T315I]. All other deuterium uptake curves for all other
regions showed no significance difference between wild-type and
T315I and are therefore not shown. The location of each peptide,
according to the labels A-H, is shown on the crystal structure at
the right (PDB 1OPL). Coloring is as in Figure 3: obvious changes
(colored hot pink) were defined as a difference between deuterium
exchange-in curves of 1.0 Da or more. Subtle changes (colored
light yellow) were 0.4-1.0 Da. No changes were differences of 0.0-
0.4 Da. Residues corresponding to the hydrophobic spine M309,
L320 and F401 are colored blue and rendered as sticks. The 1OPL
crystal structure was chosen to display these data because we
observed subtle changes in regions outside of the kinase domain,
namely in the SH2 domain residues 137-157. Abl kinase is
believed to adopt an extended top-hat conformation illustrated by
this crystal structure (see main text).
(TIF)
Figure S4 Example mass spectra for selected regions, intended
to illustrate the quality of data for all experiments. A. Residues
287-298 (peptide m/z =682.3
+2). B. Residues 325-335 (peptide
m/z =683.4
+2). C. Residues 525-534 (peptide m/z =543.8
+2). A
dotted line is provided at the same m/z in both free or bound data
to guide the eye.
(TIF)
Figure S5 Location key for Figures 2 and 3, on PDB 2F4J. Each
peptide is colored, according to the scale shown, and the residue
numbers indicated [we are numbering according to Abl 1a
numbering].
(TIF)
Figure S6 Expanded view of the myristic acid pocket. A. Ribbon
diagram, B. space filling model, in the same orientation as A. This
model was created with two crystal structures: PDB 2FO0 and
PDB 2F4J were overlaid and aligned. Then, only the aI helix is
shown for the 2F4J structure as the rest of the structure was
essentially identical to 2FO0. The aI helix for 2F4J is shown in
green/blue. In 2FO0, the aI helix is broken into two smaller
helices, aI and aI’ where an almost 90 degree bend is introduced
between aI and aI’. The peptide spanning residues 516-524 is
shown in red (2FO0) or blue (2F4J). Changes in HX are colored as
in Figure 3: obvious changes were defined as a difference between
deuterium exchange-in curves of 1.0 Da or more. Subtle changes
were 0.4-1.0 Da. No changes were differences of 0.0-0.4 Da.
(TIF)
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